Here's Why Grail Stock Bounced Back 16% Today
2026-02-24 14:13:58 ET
Grail (NASDAQ: GRAL) stock rose by more than 16% by midday. The move follows a couple of days of brutal declines after the release of top-line results from its three-year, 142,000-person trial of its Galleri multi-cancer early detection (MCED) test with England's National Health Service.
I discussed the stock's decline on the f irst day of trading after the release, and the market punished it again on Monday . However, let's focus on why the market may be optimistic about future developments.
As a reminder, the primary endpoint of the trial (which it missed) was to achieve a statistical significant reduction in combined Stage III and Stage IV cancers across 12 deadly indications.
NASDAQ: GRAL
GRAL Trading
3.38% G/L:
$49.27 Last:
319,603 Volume:
$50 Open:
